Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Bain Capital, a ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Japan’s Mitsubishi Chemical Group has resolved, at a meeting of the board of directors held today, to transfer its consolidated subsidiary, Mitsubishi Tanabe Pharma (MTPC), which engages in the ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

The Osaka-based firm has a pipeline of drugs relating to the central nervous system, immuno-inflammation and oncology ...